Complete Response Letter

A Complete Response Letter (CRL) is the FDA’s notice that it will not approve a drug in its current form, listing the deficiencies that must be resolved. A CRL is not a permanent rejection, but it typically delays approval by months to years and often triggers a sharp stock decline.